You might have caught Pharmalot’s piece on the recently passed Mass. legislation that will codify pharmaceutical marketing to healthcare practitioners. The article describes Lilly CEO John Lechleiter’s response to the measure, which was harsh, essentially threatening to caught off Mass. from future Lilly R&D investments:
Such work is the backbone of research and development in biotechnology and [...]
More on this topic
(What's this?)
The “Biotech Super Bowl” Starts Tomorrow… Are You Ready?
(Investment U, 6/3/10)
The American Biotech Revolution: How to Invest in The Biotechnology Sector
(Investment U, 5/14/10)
“The End of the Grey Plague”
(Stock Gumshoe, 7/5/10)
“Bio Seeds — California Biotech Cleared to Bypass FDA – Next Month – for 22,627% Gains”
(Stock Gumshoe, 6/17/10)
